Omez DSR

Quick links to important sections

Omez DSR

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Omez DSR

Property Description
Active Ingredients Omeprazole and Domperidone
Form Oral Capsule (Dual-Release System)
Pharmacological Class Proton Pump Inhibitor (PPI) and Prokinetic/Dopamine Antagonist
Common Use Addressing acid hypersecretion and reduced gut motility
Origin Synthetic

What Type of Medicine is Omez DSR?

Omez DSR is classified as a fixed-dose combination (FDC) preparation, which unites two distinct synthetic active ingredientsOmeprazole and Domperidone—within a single unit. This formulation is designed to deliver a dual therapeutic action. The dual identity is defined by the two primary pharmacological classes to which its components belong: Omeprazole is a Proton Pump Inhibitor (PPI), and Domperidone functions as a Dopamine Antagonist and prokinetic agent.

The preparation is an oral dosage form, specifically a capsule, engineered with a specialized dual-release system. This system differentiates it from simple, immediate-release combinations or single-ingredient products. The Omeprazole component is protected within delayed-release (DR) enteric-coated granules, a feature designed to maximize its absorption, while the Domperidone component is formulated for extended-release (DSR) to sustain its action over a longer duration.

What is the General Purpose of the Omeprazole-Domperidone Combination?

The general purpose of this combination medicine is to provide relief for upper digestive issues by simultaneously addressing excess acid production and promoting normal gut function. This approach targets gastrointestinal complaints where both factors are present. The medicine is designed to tackle two root causes: stomach acid hypersecretion and impaired gastrointestinal motility.

The synergistic effect of the combination is key. The Omeprazole component achieves gastric acid suppression by targeting the final stage of acid production. Domperidone acts to speed up gastric emptying and strengthens the lower esophageal sphincter, which acts as a physical barrier to reflux. This combination manages symptoms resulting from both acid and delayed gut transit, making it suitable for scenarios involving simultaneous heartburn and the feeling of excessive stomach fullness.

What side effects are possible with Omez DSR?

Possible Side Effects and Safety Information

The safety profile of this medicine is based on the documented characteristics of its two active ingredients, Omeprazole and Domperidone, as classified by government regulatory authorities.

Adverse reactions are grouped by frequency of occurrence and the System Organ Class (SOC) affected. Common effects, which are more likely to appear at treatment initiation, primarily involve the Gastrointestinal and Nervous Systems. These commonly listed reactions include headache, diarrhoea, abdominal pain, nausea, and dry mouth.

Serious Adverse Reactions

The official label documents rare but serious adverse reactions. The Domperidone component is associated with risks of serious ventricular arrhythmias and QT interval prolongation, which is a key reason for the strict safety constraints in the label. The Omeprazole component is associated with rare severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS), as well as anaphylactic reactions.

Safety Restrictions and Special Populations

Safety notes specify contraindications for patients with certain pre-existing conditions. The medicine is formally contraindicated in individuals with known pre-existing cardiac conditions or those with severe hepatic impairment. Furthermore, official regulatory information specifies that older adults (over 60 years) have an increased risk of cardiac side effects. Risks associated with long-term exposure to the Omeprazole component include the potential for fundic gland polyps and hypomagnesemia.

Overdose and Emergency Response

The official regulatory profile for Omez DSR overdose is defined by the documented risks associated with its two active components, requiring specific emergency actions.

Documented Overdose Manifestations

Overdose presentations documented in official sources may include central nervous system effects such as somnolence (drowsiness), disorientation, and extrapyramidal symptoms (involuntary body movements). Other officially listed signs include tachycardia (fast heart rate), nausea, vomiting, and headache.

Severe Outcomes and Emergency Action

A potentially life-threatening outcome explicitly documented in regulatory information, primarily linked to the Domperidone component, is the risk of QT prolongation. This can lead to serious cardiac arrhythmias and, in rare instances, cardiac arrest.

Due to the potential for these severe manifestations, regulators mandate that individuals seek immediate medical attention or contact emergency services right away if an overdose is suspected, even if symptoms are not fully apparent.

Management and Monitoring Requirements

The management approach specified in official documents is symptomatic and supportive treatment, as no specific antidote is known. Procedures such as gastric lavage or administration of activated charcoal may be considered. Close ECG monitoring is required in a hospital setting to observe the patient's heart function. Increased risk of severe outcomes is noted for infants and children and individuals with pre-existing cardiac or renal conditions.

Therapeutic Uses of Omez DSR

What Omez DSR Treats: Main Uses and Benefits


Omez DSR is a combination therapy for use in situations involving certain distressing symptoms. This dual approach is commonly used in contexts involving a heightened burden in the digestive tract.

The medicine is relevant in conditions characterized by periods of heightened symptoms, such as Gastroesophageal Reflux Disease (GERD) and dyspepsia (indigestion). This combination is intended for managing symptoms associated with gastroparesis and gastroesophageal reflux. This typically includes physical discomfort such as heartburn, as well as symptoms like nausea and bloating. The formulation is designed to help ease the overall symptom burden and may assist with maintaining functional stability.

“The combination is applied in addressing symptoms that interfere with daily functioning and is relevant for easing discomfort during periods of heightened symptoms.”

Quick Fact: Commonly used for managing Heartburn and Bloating

Eligibility and Restrictions for Use

Eligibility Scope for Omez DSR

The eligibility profile for the Omeprazole and Domperidone combination is highly restrictive, primarily governed by the cardiac and hepatic safety requirements of the Domperidone component, as defined by global regulatory bodies.

Category Official Regulatory Classification
Populations for whom use is allowed Adults (Established as the standard eligible population for use under labeled conditions).
Populations for whom use is contraindicated Patients with pre-existing cardiac conduction issues (e.g., QTc prolongation), significant electrolyte disturbances (e.g., hypokalemia), or underlying cardiac diseases such as congestive heart failure. Patients with moderate or severe hepatic impairment (liver disease) or a prolactinoma (a pituitary tumor).
Age-related eligibility rules Children and Adolescents (generally under 12 years of age) are contraindicated or categorized as use not established for the FDC. Geriatric Patients (ge 60 or ge 65 years) require special consideration due to increased cardiac risk.
Condition-specific eligibility rules Contraindicated in cases of gastrointestinal hemorrhage, mechanical obstruction, or perforation. Concomitant use with specific QT-prolonging drugs or potent CYP3A4 inhibitors is strictly contraindicated.
Pregnancy and lactation eligibility status Not Recommended during pregnancy or lactation as components pass into breast milk.

Official regulatory documents define who can and cannot use this medicine by imposing stringent restrictions based on patient comorbidities and physiological status. Eligibility is therefore limited primarily to adults who lack these severe contraindicating conditions, while use is formally prohibited in patients with certain heart or liver impairments.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The regulatory profile for Omez DSR defines specific restrictions based on the properties of its two components. The Domperidone component is associated with high-risk contraindicated combinations. Co-administration with QTc-prolonging medicinal products (e.g., certain antibiotics and anti-arrhythmics) is formally prohibited due to the risk of additive QTc prolongation. Similarly, potent CYP3A4 inhibitors (e.g., systemic azole antifungals like Ketoconazole and certain HIV protease inhibitors) are contraindicated as they significantly increase Domperidone's plasma concentration.

The Omeprazole component primarily causes pharmacokinetic alterations through enzyme inhibition. Omeprazole can reduce the pharmacological activity of the anti-platelet medicine Clopidogrel; this combination is officially to be avoided. Omeprazole can also prolong the elimination of drugs like Phenytoin and Warfarin. Furthermore, the acid-suppressing effect of Omeprazole interferes with the absorption of certain medicines, such as Iron salts and Digoxin, whose bioavailability depends on gastric pH.

Official warnings note that combinations with CYP enzyme inducers like the herbal product St. John's Wort are to be avoided, as they may reduce Omeprazole concentrations. Regarding population-specific interaction considerations, Domperidone is formally contraindicated in moderate to severe hepatic impairment. Antacids and other antisecretory agents should not be taken simultaneously with the medicine, as they lower the oral bioavailability of Domperidone.

Mechanism of Action

How Omez DSR Works: Mechanism of Action

Sustained Inhibition of Gastric Acid Production

This mechanism involves the irreversible blockade of the H^+/ K^+-ATPase enzyme, or Proton Pump, located in the secretory canaliculi of the stomach's parietal cells . The active component, a prodrug, is activated by acid and subsequently forms a covalent bond with the pump, effectively stopping the final step of acid secretion. The resulting physiological effect is a long-duration reduction in the stomach's hydrogen ion concentration, which fundamentally modulates the chemical environment of the upper GI tract.

Enhanced Movement of the Upper Digestive Tract

This domain centers on the antagonism of peripheral D2 dopamine receptors in the smooth muscles of the esophagus and stomach. By blocking these inhibitory receptors, the drug increases the release and effectiveness of acetylcholine, a signaling molecule that enhances muscle contraction. This action leads to the physiological outcome of increased velocity and force of digestive content propulsion and enhanced muscle tone. The overall mechanism is derived from the concurrent influence on two distinct physiological processes: limiting the release of gastric acid and simultaneously increasing the rate of gastric emptying, thus determining the observable physiological consequences within the upper gastrointestinal system.

Dosage and Administration Information

The administration of the Omez DSR fixed-dose combination is based on an oral protocol. The product consists of a single capsule containing Omeprazole 20 mg and Domperidone 30 mg in a dual-release formulation.

Standard Administration

Instruction Detail
Route of administration Oral route.
Dosing schedule One capsule (Omeprazole 20 mg / Domperidone 30 mg).
Frequency Twice daily (every 12 hours).
Timing to meals Must be taken before a meal, generally 15 to 30 minutes prior to eating.
Special procedure The capsule must be swallowed whole with water and must not be crushed or chewed.

Use Protocol and Adjustments

The combination is intended for short-term use, with courses often lasting up to four to eight weeks. The required administration frequency is twice daily, and the daily dose must not be doubled if a dose is missed.

Dosing involves specific considerations for certain patient groups. Dosing frequency of the Domperidone component may require reduction in patients presenting with severe renal impairment. Furthermore, careful dose consideration is also relevant for patients with hepatic impairment or those categorized as older adults.

Recent Clinical Evidence

Omez DSR: Recent Clinical Evidence

Evidence for use in Gastroesophageal Reflux Disease (GERD)

The omeprazole-domperidone combination was studied for its use in Gastroesophageal Reflux Disease (GERD). The primary evidence includes Randomized Controlled Trials (RCTs) and Systematic Reviews involving adults who had symptoms where intensity may vary. Researchers focused on outcomes related to physical discomfort, such as symptom change and the healing status of esophagitis. Studies examined differences in measurements of symptom resolution and periods of less discomfort between the combination and omeprazole monotherapy.


Evidence for use in Functional Dyspepsia and Associated Conditions

The combination was studied for its application in functional dyspepsia and related Acid Peptic Disease (APD) symptoms. This research structure includes Prospective Observational and Retrospective Real-world Studies. These studies applied in studies examining patient-reported experiences of epigastric burning, fullness, and nauseaoutcomes related to systemic or functional imbalance. Research describes patterns where measurements of symptom severity and frequency evolved in the observed populations. Evidence in this area is limited by reliance on observational settings, and comparative evidence is lacking against other standard therapies.


Long-Term Outcomes, Subgroups, and Research Uncertainty

Most RCTs involve short-term follow-up, typically 4 to 8 weeks. Researchers acknowledge that long-term effects are not fully established, and certainty remains low regarding the durability of observed patterns over many months. Data for certain groups remain insufficient, including older adults or children. One specific area of research was evaluated in adult patients with Type 2 Diabetes Mellitus, but these subgroup findings are uncertain when generalized to the broader public. Sample sizes were modest in some pivotal trials, and Study results reflect the specific conditions under which they were conducted.

Key Studies & References

  1. Efficacy and Safety of Domperidone in Combination with Proton Pump Inhibitors in Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
  2. Systematic review and network meta-analysis: efficacy of drugs for functional dyspepsia
  3. CARDIAC SAFETY AND CLINICAL EFFICACY OF DOMPERIDONE USE IN GASTROPARESIS USING AN FDA APPROVED IND PROTOCOL: A PROSPECTIVE 11-YEARS STUDY

Frequently Asked Questions (FAQ)

Common questions about Omez DSR (FAQ)


Q: Is Omez DSR the same as Omeprazole?

Omez DSR is a combination product that contains two active ingredients: Omeprazole (a proton pump inhibitor) and Domperidone (a prokinetic agent). Therefore, it is not the same as taking Omeprazole alone. The combination is designed to provide both acid reduction and improved gut movement.


Q: What is the DSR part of Omez DSR?

DSR typically stands for a Dual or Delayed and Sustained/Prolonged Release system. This refers to the special way the medicine is formulated. The system is engineered to ensure the Omeprazole component is delayed-release and the Domperidone component is released more slowly over time for sustained action.


Q: How long does it typically take for Omez DSR to start working?

Official information indicates that the acid-reducing effect of the Omeprazole component usually begins within one hour after taking the capsule. The maximum acid-suppressing effect may be observed around two hours after administration. Full symptom control may take a few days of consistent administration to be observed.


Q: What is the role of Domperidone in Omez DSR?

Domperidone is classified as a prokinetic agent, meaning it helps to improve the movement of the gut. Its role in Omez DSR is to increase the force and speed of muscle contractions in the stomach and intestines. This action is intended to increase the rate of gastric emptying, which addresses symptoms related to stomach fullness.


Q: Does Omez DSR help with gas or bloating?

Official indications for the Domperidone component include managing symptoms related to delayed stomach emptying, such as bloating and the feeling of excessive stomach fullness (epigastric distension). Regulatory documents also list gas (flatulence) as a common side effect.


Q: Can Omez DSR be used for stomach ulcers?

The Omeprazole component is officially indicated for the treatment of stomach (gastric) and duodenal ulcers. The Omeprazole component’s indication for ulcers means the combination is used for conditions where both acid and motility issues are present.


Q: Can Omez DSR interact with herbal remedies?

Yes, official warnings specifically advise against using the medicine alongside certain enzyme-inducing herbal products, such as St. John's Wort, because they may reduce the concentration and effectiveness of the Omeprazole component. For other supplements, potential interaction depends on how they are metabolized.


Q: Is Omez DSR linked to any long-term bone density concerns?

Regulatory documents for the Omeprazole component mention that the use of proton pump inhibitors, particularly over long periods (typically longer than one year), has been associated with an increased risk of fractures in the hip, wrist, or spine in some studies. The potential for this association is noted in the official warnings for Omeprazole.


Q: Can I take other stomach medicines (like Rennie or Gaviscon) while using Omez DSR?

Official guidance notes that antacids and other acid-suppressing agents may reduce the absorption and effectiveness of the Domperidone component. Simultaneous use is generally noted to interfere with Domperidone absorption, which may affect the combination's therapeutic action.


Q: Why is the drug sometimes called a 'prokinetic' medicine?

The medicine is called a 'prokinetic' because the Domperidone component is a prokinetic agent. This class of medicine is designed to enhance or improve the muscle movement (motility) of the upper digestive tract. This action helps to speed up the passage of stomach contents.


Q: Can Omez DSR affect laboratory test results?

Official regulatory information indicates that the Omeprazole component can interfere with certain types of laboratory tests. Specifically, it may affect tests for Chromogranin A (CgA), which is sometimes used as a tumor marker, which may potentially lead to inaccurate results.


Q: Can Omez DSR be stopped suddenly, or does it need to be tapered?

Regulatory guidance suggests that discontinuing acid-blocking medicines, especially after prolonged use, may lead to a temporary return of acid symptoms (known as rebound acid hypersecretion). Information suggests that sudden stopping may not be advisable due to this potential for rebound.


Q: Does Omez DSR cause headaches?

Yes, regulatory documents list headache as a side effect that is common with the use of this medicine. Headaches are listed among the common adverse events associated with the use of the medicine.


Q: Is Omez DSR safe to take every day?

The officially recommended regimen for Omez DSR requires the medicine to be taken twice daily (every 12 hours) for the entire prescribed course. This daily administration is consistent with the drug’s design, but official guidance specifies that the medicine is intended for short-term use.


Q: Is there a maximum amount of time Omez DSR should be taken?

Official guidelines indicate that the Omeprazole-Domperidone combination is designated for short-term use, often prescribed for a course lasting up to four to eight weeks. This duration is noted in the regulatory documents for the combination product.


Q: Can Omez DSR cause trouble sleeping or insomnia?

Official documents for the Omeprazole component list insomnia (trouble sleeping) as an uncommon (less frequent) side effect that has been reported by users. Other central nervous system effects, such as confusion, have been reported in rare instances.


Q: Are there any common foods or drinks to avoid while taking Omez DSR?

Official warnings sometimes advise against the co-ingestion of certain foods or drinks, such as grapefruit juice, as it may affect the concentration of the Domperidone component. This is due to its effect on certain metabolic enzymes.


Q: Does Omez DSR affect the absorption of vitamins or minerals?

Yes, official warnings note that the Omeprazole component, like other acid-blocking medicines, may reduce the absorption of vitamin B12 (cyanocobalamin). This reduction in absorption is noted as a possibility with long-term acid suppression.


Q: Is it common to experience dry mouth when taking Omez DSR?

Yes, regulatory documents list dry mouth as a side effect that is considered common with the use of the medicine. It is categorized among the more frequent adverse reactions noted in official product information.


Q: Is there any research on Omez DSR use during pregnancy or breastfeeding (descriptive only)?

The medicine is not recommended for use during either pregnancy or lactation. Regulatory documents confirm that the Domperidone component is excreted into human breast milk, and Omeprazole crosses the placenta, which is the basis for the official statement that the medicine is not recommended during these periods.


Q: Does Omez DSR cause changes in mood or anxiety?

While not a common effect, regulatory documents for the Omeprazole component include 'Psychiatric disorders' among reported side effects. These reports have included rare instances of confusion or hallucinations.


Q: Is Omez DSR a prescription-only medicine?

Yes, due to the specific cardiac safety restrictions and the mandatory specialist oversight required for the Domperidone component, Omez DSR is generally classified by regulatory bodies as a prescription-only medicine.


Q: What if Omez DSR doesn't seem to be working after a week?

The full acid-suppressing effect of the Omeprazole component is typically reached after about four days of repeated daily administration. If symptom control is not achieved after a full course of treatment, official guidance indicates that further assessment is typically considered.


Q: Is Omez DSR effective for all causes of indigestion?

The medicine is officially indicated for indigestion symptoms linked to two specific issues: acid hypersecretion and/or impaired gut motility. It is not designed to treat all possible causes of indigestion, such as those related to mechanical blockages or infections.


Q: Is there a generic version of Omez DSR available?

Since the active ingredients, Omeprazole and Domperidone, are widely known, multiple pharmaceutical companies often produce combination products containing the same components. These are often considered generic equivalents and may be available under different brand names.


Q: Does Omez DSR help with acid reflux symptoms at night?

The dual-release formulation is engineered to provide sustained action throughout the day. This design is intended to address symptoms (like acid reflux and stomach fullness) that may occur over a 24-hour period.


Q: Why do some people take Omez DSR in the morning?

The Omeprazole component, which blocks stomach acid production, is most effective when taken before the body’s morning surge of acid. Taking the first dose in the morning before breakfast is a common protocol for this type of acid-suppressing medicine.


Q: Is Omez DSR considered a long-term treatment option?

Official documentation specifies that the Omeprazole-Domperidone combination is indicated for short-term use, typically for a maximum course of four to eight weeks. It is not designated as a long-term or chronic treatment option.


Q: Are there reported interactions between Omez DSR and supplements?

Official warnings mention that the effectiveness of Omeprazole can be reduced by enzyme inducers like the herbal product St. John's Wort. For other dietary supplements, the potential for interaction depends on how they are metabolized by the body.


Q: Does Omez DSR make you feel drowsy or dizzy?

Yes, regulatory documents list both dizziness and drowsiness as side effects that have been associated with the use of the medicine. These effects are related to the nervous system and are included in the list of official adverse events.


Q: What are some less common but serious side effects of Omez DSR to be aware of?

Serious but rare side effects reported in official documents include rare severe skin reactions (like Stevens-Johnson syndrome), severe allergic reactions (anaphylactic reactions), and serious ventricular arrhythmias (irregular heartbeat), which is linked to the Domperidone component.

How should Omez DSR be stored and disposed of?

Storage and Disposal of Omez DSR

Official regulatory documents define specific requirements to maintain the stability of Omez DSR (Omeprazole and Domperidone combination) capsules.

Storage Requirements

The medicine must be stored at a temperature not exceeding 30 C and must be protected from light and moisture. To maintain integrity, the capsules must be kept in their original container or package. It is a mandatory requirement to store the medicine out of the sight and reach of children.

Disposal Instructions

Any unused or expired product must be disposed of in accordance with local requirements. Government guidance generally advises against disposing of medicines via wastewater or household waste to ensure environmental protection and public safety. Check with a pharmacist or local collection point for appropriate disposal methods.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Omez DSR found in:

A-Z Index: